49 results about "Streptococcus salivarius" patented technology

A process for enzymatic preparation of a highly linear poly(α 1, 3 glucan) from sucrose is disclosed. The glucosyltransferase enzyme (gtfJ) from Streptococcus salivarius is used to convert sucrose to a highly linear poly(α 1, 3 glucan) in high titers. Hydrolyzed poly(α 1, 3 glucan) is used as the primer for the gtfJ enzyme reaction resulting in the formation of highly linear poly(α 1, 3 glucan).

The invention relates to a group of alive microbial preparations for preparing compound microbial fertilizer and the preparation method thereof. The alive microbial preparations include a microbial inoculant and an organic material degradation agent. The microbial inoculant includes Bacillus megaterium, Bacillus licheniformis, Bacillus mucilaginosus, Bacillus laterosporus, Azotobocter chroococcum, etc. The organic material degradation agent includes Bacillus megaterium, Bacillus licheniformis, Bacillus subtilis, Bacillus circulans, Saccharomyces cerevisiae, Candida lipolytica, Bacillus pumilus, Bacillus cereus, Streptomyces griseus, Pseudomonas alcaligenes, Pseudomonas cepacia, Streptococcus salivarius subsp. Thermophilus, Geobacillus stearothermophilus, Streptomyces Thermophilus, Geotrichum candidum and Aspergillus oryzae. The preparation method comprises the following steps: carrying out submerged fermentation, directly mixing the bacterial liquids and stirring to obtain a liquid preparation; or mixing with an absorbent to obtain a solid preparation. The alive microbial preparations have the advantages of improving soil fertility, promoting plant growth, enhancing anti-disease, anti-insect and anti-drought capacities of plants, improving quality of agricultural products and so on.

Disclosed herein are probiotic compositions comprising a mixture of at least two probiotic bacteria, including Streptococcus salivarius K12® (BLIS K12®) and at least a Lactobacillus bacteria. The Streptococcus salivarius K12® (BLIS K12®) may comprise Streptococcus salivarius K12® (BLIS K12®) BAA1024. The Lactobacillus bacteria may be selected from those known to be suitable for oral administration, for example from those known to improve recipient health, particularly recipient oral health.

This invention relates to methods for inhibiting growth of anaerobic bacteria, particularly halitosis causing bacteria. The methods use BLIS-producing Streptococcus salivarius strains, extracts thereof, and compositions comprising same in the prevention or treatment of halitosis.

The invention discloses a composition capable of reducing halitosis and application thereof. The composition comprises composite probiotics, the composite probiotics comprise lactobacillus salivarius,bifidobacteria, lactobacillus rhamnosus, lactobacillus acidophilus, lactobacillus reuteri, streptococcus salivarius and lactobacillus johnsonii, wherein each gram of composition at least contains 2 billions of lactobacillus salivarius, 1 billions of bifidobacteria, 2 billions of lactobacillus johnsonii, 4 billions of lactobacillus rhamnosus, 2 billions of lactobacillus acidophilus, 2 billions oflactobacillus reuteri and 2 billions of streptococcus salivarius. The composition can also be widely applied in the preparation of drugs for treating halitosis, oral care products, cosmetic compositions, food or health-care products. Compared with the prior art, the composition disclosed by the solution of the invention can treat both intra-oral halitosis and extra-oral halitosis, and has the advantages of good therapeutic effect, broad application prospect and the like.

The invention provides application of salivaricin in preparation of medicines for preventing and/or treating autoimmune diseases, belonging to the technical field of treatment of the autoimmune diseases. The salivaricin is an antibacterial peptide synthesized and secreted by streptococcus salivarius and plays an important role in maintenance of the local micro-ecological balance of the mucosa. Thesalivaricin can significantly promote the secretion of an anti-inflammatory cytokine IL-10 and inhibit the expression of the pro-inflammatory cytokines IL-17, IL-21 and TNF-alpha. Furthermore, the salivaricin can up-regulate the proportion of anti-inflammatory cell regulatory T (Treg) cells, and down-regulates the proportion of pro-inflammatory cell follicular helper T cells and helper T-17 cellsin immune cell subsets. The salivaricin can relieve an immune imbalance state by inhibiting an immune response, reestablishes the immune balance, and provides a new treatment method for the autoimmune diseases such as rheumatoid arthritis.

This invention provides novel Streptococcus salivarius, compositions containing same, and use of S. salivarius strains as antimicrobial agents. The strains are bacterial inhibitors with respect to at least S. mutans and/or MS and therefore have a number of therapeutic applications. The applications include but are not limited to forming part of therapeutic formulations for use in controlling, treating, or preventing dental caries.

The invention discloses probiotic composition. The probiotic composition comprises Lactobacillus acidophilus, streptococcus salivarius M18 and streptococcus salivarius K12. By means of the probiotic composition, regeneration of damaged alveolar bone is facilitated, growth of periodontal pathogens can be inhibited, periodontitis can be prevented and treated to a certain degree, periodontal diseasescan be inhibited effectively, and the problem of unhealthy teeth of modern people is solved.

The invention provides a Streptococcus salivarius strain whose preservation number is CGMCC NO. 13308. The invention further provides application of the Streptococcus salivarius CGMCC NO. 13308 in preparation of a Streptococcus mutans growth inhibitor and a Streptococcus mutans biomembrane formation inhibitor. The new Streptococcus salivarius CGMCC NO. 13308 is disclosed for the first time, cells of the Streptococcus salivarius CGMCC NO. 13308 have the function of inhibiting growth of Streptococcus mutans, and the M17 fermented supernatant fluid can obviously reduce the formation amount of Streptococcus mutans biomembrane. By means of the Streptococcus salivarius strain and its application, the application prospects and industrialized resources of Streptococcus salivarius in the aspect of dental caries are broadened.

The invention discloses an application of lactobacillus paracasei L9 to prevention or treatment oral disease and regulation of oral cavity flora. L9 can be used for preparing a medical composition anda food for preventing or treating dental caries. Research proves that L9 can notably relieve generation degree of occlusal surface E-level dental caries, after the LP is taken, the structure of the oral cavity flora is changed notably, particularly actinobacteria is notably increased, the actinobacteria of L9 group is obviously reduced, klebsiella, aerococcus, Gemella, corynebacterium and pseudomonas aeruginosa on the classification level are notably reduced, and the oral disease risk is reduced. When L9 is taken, the saliva species richness is notably reduced, the relative abundance of oraldisease relevant fungi of streptococcus salivarius, actinomycetaceae, peptostreptococcus and the like is notably reduced, and the L9 can have relieving effects on periodonitis diseases. The dental plaque flora species diversity is notably reduced, the relative abundance of leptothrix, fusobacteriaceaeand flavobacterium is notably reduced, and the L9 can have relieving effects on oral diseases of periodontal disease, halitosis, dental caries and the like.

The invention discloses a kit for identifying colorectal cancer. The kit is characterized by comprising a specific primer combination for identifying indicating bacteria, wherein the primer combination is shown as SEQ ID NO.1-12, and the indicating bacteria are a combination of F. nucleatum, P. anaerobius, C. symbiosum, E. faecalis, P. asaccharolytica and S. salivaricus. The invention also discloses an application of the kit. The kit has the beneficial effects that risk prediction of colorectal cancer can be carried out only by collecting stool samples. The principle is to detect colorectal cancer pathogenic bacteria in feces, wherein the risk assessment sensitivity can reach 92% and the specificity is 95%.

The invention discloses intestinal microorganism markers for detecting multiple myeloma diseases, and an application and detection preparation of the intestinal microorganism markers. The intestinal microorganism markers comprise citrobacter freundii, enterobacter cloacae, raoultella ornithinolytica, klebsiella aerogenes, klebsiella variicola, klebsiella pneumoniae, streptococcus salivarius, streptococcus oralis, streptococcus gordonii, streptococcus mitis, streptococcus pneumoniae, butyrate producing bacteria, clostridium butyricum and clostridium saccharobutylicum. The intestinal microbial markers can be used alone or in combination. The invention discloses a support vector machine (SVM) classification model constructed by taking the microbial markers as characteristics, and the SVM classification model is applied to clinical diagnosis of multiple myeloma diseases. The invention also discloses an application of the microorganism markers in preparation of a diagnostic preparation formultiple myeloma diseases.

The invention provides a bergenia crassifolia extract and an extracting method and medical application in oral diseases. Through a resazurin dyeing method and an XTT method, the extract of bergenia crassifolia is subjected to bacteriostatic activity and inhibitory biological film activity study, the extract of bergenia crassifolia has an obvious inhibitory effect on streptococcus mutans, streptococcus sanguis, streptococcus salivarius, lactobacillus acidophilus, porphyromonas gingivalis, fusobacterium nucleatum, actinobacillus actinomycetemcomitan and biological film of the fungi, has a better inhibitory effect on streptococcus mutans, porphyromonas gingivalis and the biological film of the fungi and can be used for preparing daily necessities and medicine for preventing and treating the oral diseases.

The invention discloses a kit for detecting colorectal cancer indicator bacteria. The kit is characterized by comprising the following components: a specific primer combination for identifying the indicator bacteria, wherein the primer combination is shown as SEQ ID NO. 1-14, and the indicator bacteria are the combination of fusobacterium nucleatum (F.nucleolus), anaerobic digestion streptococcus(P.anaerobicus), clostridium symbiosum (C.symbiolum), Porphyromonas saccharolytica (P.asaccharolytica), Prevotella intermedia (P.intermedia), Bacteroides fragilis (B.fragilis) and Streptococcus salivarius (S.salivarius). The kit for detecting colorectal cancer indicator bacteria disclosed by the invention has the beneficial effects that the colorectal cancer can be identified only by collecting astool sample. The principle is that the aim of identifying the colorectal cancer by detecting the colorectal cancer pathogenic bacteria in excrement, the sensitivity can reach 92.9%, and the specificity is 92.6%.

The invention discloses a composition, application thereof and an oral preparation capable of improving the oral health. According to the composition, by adding 1-20 parts of lactobacillus rhamnosus R11, 1-20 parts of streptococcus salivarius blis K12 and 1-20 parts of lactobacillus reuteri HA188 (in parts by weight), the effect of probiotics on the improvement of the oral health is obviously improved; by further adding one or more of lactobacillus helveticus Lafti L10, saccharomyces cerevisiae boulardii, folic acid compounds, coenzyme Q10, vitamin C, fructo-oligose, xylooligosaccharide and galactooligosaccharide, the effect of the composition on the improvement of the oral health can be further improved; and an unexpected discovery shows that by adjusting the addition weight ratio of streptococcus salivarius blis K12 to lactobacillus reuteri HA188, the light degradation rate of the folic acid compounds in the composition can be remarkably decreased. The composition prepared by virtueof an equivalent gradient premixing method can be used for preparing the oral preparation capable of improving the oral health.

The invention provides a fermented crude extract of streptococcus salivarius, and a preparation method and application thereof. The preparation method comprises the following steps of (1) inoculating streptococcus salivarius CGMCC NO.13308 into an M17 culture medium containing saccharose, fermenting to obtain fermentation liquor, and centrifuging the obtained fermentation liquor to obtain a supernate; (2) adding ammonium sulfate into the supernate obtained through the step (1), centrifugally collecting sediments precipitated when the saturability of the ammonium sulfate is 40 to 80 percent, dissolving the obtained sediments, carrying out dialysis, freezing and drying to obtain the fermented crude extract of the streptococcus salivarius. The invention adopts a streptococcus salivarius CGMCC NO.13308 strain for preparing the fermented crude extract for the first time, the fermented crude extract of the streptococcus salivarius has an inhibitory effect on a streptococcus mutans biological membrane, and discloses that the streptococcus salivarius CGMCC NO.13308 has a new function of being fermented to produce a streptococcus mutansbiological membrane forming inhibitor, and the source of the streptococcus mutans biological membrane forming inhibitor is widened.

The invention relates to the technical field of microbial preparations, in particular to a probiotic microecological preparation for treating oral halitosis and inflammation as well as a preparation method and application thereof. The probiotic microecological preparation comprises the following raw materials in parts by weight: 5-80 parts of probiotics, 1-40 parts of a functional sweetening agent, 1-20 parts of maltodextrin and 2-10 parts of freeze-dried fruit powder, wherein. the probiotics comprise streptococcus salivarius k12. All the component substances are compounded to generate a synergistic effect, so that various nutrients are provided for consumers, the probiotic effects of better protecting oral cavity health care and the like are achieved, and an important effect is achieved on prevention of oral diseases such as periodontitis, decayed teeth, halitosis and oral ulcer.

This invention relates to a urase gene of streptococcus salivarius, concretely, concerning about a 57.I urase gene of streptococcus salivarius and its urase. A 57.I urase gene of streptococcus salivarius , whose nucleotide sequence is what is described in SEQ ID NO.1. Nickel ion bonding in the gene and nucleotide sequence of transit-related gene MQO are what are described in SEQ ID NO.2. The advantage of this invention is that gaining the cloning of urase gene of streptococcus salivarius U35248 by the method of segment cloning and gradually enzyme-cutting connection ,and its object gene length proceeds to 8Kb, increasing Nickel ion bonding of the gene and transit-related gene MQO compared with existing technology , therefore, expressing ureolytic activity without adding exogenous NiCl2.Attained cloning can be used for future replacement therapy in anti-caries research building without adding exogenous NiCl2,more suitable for clinical application of production alkali effect germ.

The invention provides streptococcus salivarius and an application thereof to preparation of medicines for treatment of inflammatory bowel diseases, and relates to the field of a biological technology. The streptococcus salivarius (streptococcus salivarius) 1802 is preserved in the preservation center with the preservation number of CCTCC NO:M 2019251. A screening method of the streptococcus salivarius comprises the steps of enabling excrement of healthy people to be subjected to suspension with bacteria-free water, performing diluting until the volume is 10-6 times, and performing fractionalcultivation in a brain-heart leaching solution culture medium with a plate streak to obtain the streptococcus salivarius (streptococcus salivarius) 1802. The streptococcus salivarius (streptococcus salivarius) 1802 can be applied to preparation of medicines for treatment of inflammatory bowel diseases, can be used in medicines for relieving inflammatory reactions of the inflammatory bowel diseases, and can be applied to medicines for relieving inflammatory bowel disease colon mucous membrane injury.

The invention discloses a preparation method for a triclosan-containing polyethylene glycol-b-poly(beta-urethane-urea) polymer micelle and application of the micelle in selectively killing an oral streptococcus mutans of a biofilm. The polyethylene glycol-b-poly(beta-urethane-urea) polymer is obtained by performing Michael addition reaction on triclosan-containing monomer molecues. The triclosan-bonded polyethylene glycol-b-poly(beta-urethane-urea) polymer has relatively good killing effect on the harmful bacteria oral streptococcus mutans of the biofilm, and can selectively keep oral beneficial bacterium streptococcus salivarius. The micelle system has the advantages that: firstly, preparation is simple; secondly, large-scale preparation can be realized, and conversion to the clinical direction is easy; thirdly, biofilm infiltration capacity is good; and fourthly, selective killing ability on harmful bacteria is achieved.